ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Keytruda in recurrent HNSCC is planned for H2 this year.

May 29, 2024 - 04:00

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Keytruda in recurrent HNSCC is planned for H2 this year.

Read the original article

Tags:

Previous Article

ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient de...

Asahi Kasei offers to buy Sweden’s Calliditas for $1.04bn

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

A new study shows how Medicaid coverage policies shape maternal health disparities

A new study shows how Medicaid coverage policies shape ...

Jul 18, 2023

How smart hospitals private equity performed in the pha...

Jul 27, 2023

STAT+: Intercept, once a biotech trailblazer, sells itself for less than $1 billion

STAT+: Intercept, once a biotech trailblazer, sells its...

Sep 26, 2023